

Drugs and Devices Division

Drug Submission Status

Report for March 2019

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Cinacalcet	Sensipar	cinacalcet HCl	30mg	tablet	02478900
Auro Pharma Inc.	Auro-Cinacalcet	Sensipar	cinacalcet HCl	60mg	tablet	02478919
Auro Pharma Inc.	Auro-Cinacalcet	Sensipar	cinacalcet HCl	90mg	tablet	02478943
Auro Pharma Inc.	Auro-Gabapentin Tablets	Neurontin	gabapentin	600mg	FC tablet	02428334

Auro Pharma Inc.	Auro-Gabapentin Tablets	Neurontin	gabapentin	800mg	FC tablet	02428342
Auro Pharma Inc.	Auro-Eletriptan	Relpax	eletriptan	20mg	tablet	02479451
Auro Pharma Inc.	Auro-Eletriptan	Relpax	eletriptan	40mg	tablet	02479478
Sandoz Canada Inc.	Fulvestrant Injection	Faslodex	fulvestrant	50 mg/mL	IM solution	02483610
Marcan Pharmaceuticals Inc.	Zoledronic Acid for Injection	Zometa Concentrate	zoledronic acid	4 mg/5mL	IV solution	02472805
Jamp Pharma Corporation	Jamp-Moxifloxacin	Vigamox	moxifloxacin	0.5% w/v	ophthalmic solution	02472120